JP2001145498A - Composition collected from barley malt and having lipotropy action, and production of the same composition - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a composition having hepar adiposum depression action and taken out of malted barley, and to provided a method for producing the same composition. SOLUTION: The composition having hepar adiposum depression action is composed of an ethanol insoluble fraction comprising organic acids, proteins and hemicellulose and the ethanol insoluble fraction is taken out as follows: mold fungi belonging to Aspergillus are cultivated in scoured barley not contained barley bran and/or a crushed product of scoured barley to obtain malted barley; the malted barley is mixed with an alkali to take out an alkali soluble fraction; the alkali soluble fraction is neutralized with an acid to obtain a neutral soluble fraction; and the neutral soluble fraction is mixed with ethanol to take out the ethanol insoluble fraction.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

TECHNICAL FIELD The present invention relates to a composition obtained from barley koji and having a fatty liver inhibitory effect, and a method for producing the same. More specifically, the present invention provides a barley koji by culturing a filamentous fungus belonging to the genus Aspergillus on crushed barley or / and crushed barley barley, and adding an alkali to the barley koji to separate an alkali-soluble fraction. Neutralizing the alkali-soluble fraction with an acid to obtain a neutral-soluble fraction, and separating the neutral-soluble fraction by adding ethanol, and insoluble in ethanol containing organic acids, proteins, and hemicellulose. The present invention relates to a composition having a fatty liver inhibitory effect comprising a fraction and a method for producing the same. It should be noted that hemicellulose in the present invention is obtained by alkali-extracting a polysaccharide constituting a plant cell wall, and the hemicellulose means a non-cellulosic polysaccharide that does not contain cellulose and pectic substances. (Reference: Revised New Edition "Dietary Fiber", P19, Satoshi Inami, Shuhei Kiriyama, published on May 20, 1995 by Daiichi Shuppan Co., Ltd.)

[0002]

2. Description of the Related Art Recently, many lifestyle-related diseases caused by westernization of eating habits and changes in lifestyle have become a problem, and fatty liver has been cited as one of the factors causing such lifestyle-related diseases. Have been. Fatty liver refers to a state in which excess neutral fat has accumulated in hepatocytes of the liver.
The liver makes neutral fats for use as an energy source, some of which are stored in hepatocytes. However, when more triglycerides are stored than triglycerides consumed in hepatocytes, the triglycerides accumulate in hepatocytes and become fatty liver.
It is said that fatty liver is caused mainly by excessive intake of fat, sugar, alcohol and the like, which are raw materials of neutral fat, obesity and the like. When it comes to fatty liver, a myriad of fat clumps, called lipid droplets, form in hepatocytes, which presses other tissues in the hepatocytes, causing liver dysfunction. In particular, alcoholic fatty liver can progress to cirrhosis, and fatty liver due to obesity can cause diabetes, myocardial infarction, and arteriosclerosis.
As described above, fatty liver is a disease caused by lifestyle such as eating and drinking, and it can be said that it is one of the factors causing more serious adult diseases. Treatment of fatty liver depends on its cause, and fatty liver due to obesity requires diet and exercise. In the case of alcoholic fatty liver, it is necessary to reduce alcohol consumption. As described above, in order to treat or prevent fatty liver, it is desirable to regularly consume foods containing a component having a fatty liver inhibitory action, since a daily diet occupies an extremely large weight. .

In recent years, it has been reported that dietary fiber obtained from various cereals is effective in suppressing fatty liver.
For example, JP-A-1-242530 discloses that hemicellulose obtained by removing starch and proteins from corn bran or wheat bran and further extracting with alkali is effective in suppressing fatty liver. ing. Japanese Patent Application Laid-Open No. 05-43470 discloses that hemicellulose obtained by removing starch and proteins from corn puffer, and further hemicellulose obtained by alkali extraction, furthermore, a partially decomposed product of hemicellulose obtained by treatment with xylanase,
It is described to suppress alcoholic fatty liver. JP-A-7-147934 and JP-A-9-224608 disclose that xyloglucan, which is a polysaccharide extracted from a plant cell wall, and its enzymatically degraded product have an effect of suppressing lipid increase, and prevent or treat fatty liver. Is described as being effective. JP-A-3-2856
No. 53 discloses that oats or barley is alkali-extracted,
Protein is removed from the obtained extract, and alcohol is added to the remaining liquid to precipitate it, or the residual liquid is desalted and dried to obtain a cereal gum substance containing β-glucan as a main component. It is described as having a metabolic improving effect. JP-A-4-360835 discloses that cereals, bran, bran or hulls are defatted with an organic solvent, and the arabinoxylan obtained by performing a purification treatment such as concentration and desalting of an alkali-extracted extract is a main component. It is described that a water-soluble polysaccharide reduces alcoholic liver injury. Further, JP-A-10-165120 discloses a 60M sieve of barley bran (opening 0.25 m
m) In the passing fraction, the dietary fiber content is 40% or more, and the content of hemicellulose in the total dietary fiber content is 60%.
The above is described as having a cholesterol elevation inhibitory effect. In addition, Japanese Nutrition and Food Society General Meeting Abstracts, vol. 52, 103 (1998) shows that rats fed a high cholesterol diet were bred with barley bran, and the levels of cholesterol and triglyceride in the liver of the rats decreased. Has been reported.

[0004]

The present inventors have noticed that the above-mentioned publication describes that the water-soluble polysaccharide contained in dietary fiber has a fatty liver inhibitory effect. Since it is derived from barley, it is predicted that the water-soluble polysaccharide derived from barley contained in the barley koji may contribute to the treatment of fatty liver, and it was surprisingly studied through experiments. Indeed, they have found that a composition containing an organic acid, a protein, and hemicellulose, extracted from the barley koji, has an excellent inhibitory action on fatty liver, thereby completing the present invention. An object of the present invention is to provide a composition having an excellent inhibitory action against fatty liver obtained from the barley koji and a method for producing the same. Another object of the present invention is that the molecular weight distribution is as small as 100,000 or more, and the molecular weight is 30,000 to 10
3%, 10,000 to 30,000 4%, 3,000 to 10,000 16%, 1,000 to 3,000 51%, and 1000
The following is 26%, and the component composition is 41 ± 3% by weight of organic acid, 27 ± 3% by weight of protein, and 26 ± 3% by weight of hemicellulose, and the sugar composition obtained by hydrolysis with acid is , Xylose 60 to 70% by weight, arabinose 10 to 20% by weight,
Glucose 10-15% by weight, galactose 0-3% by weight,
Another object of the present invention is to provide a composition having an excellent inhibitory action against fatty liver, which is specified by the fact that it is 0 to 5% by weight of uronic acid.

The present inventors have conducted intensive studies through experiments in view of the above-mentioned prior art. That is, the present inventors
Through an experiment described later (Experiment 1), barley koji was pulverized to obtain a barley koji pulverized product, and orotinic acid was mixed with the pulverized barley koji and administered to rats to conduct an experiment. As a result, the liver weight, liver total lipid concentration, liver cholesterol concentration, and liver triglyceride concentration of the rat showed values slightly shifted toward the normal value direction of the basal diet, and the serum total cholesterol concentration, serum HDL-cholesterol concentration, serum The triglyceride concentration and the serum phospholipid concentration also slightly shifted toward the normal value direction of the basal diet, indicating that the occurrence of fatty liver was slightly suppressed.

Therefore, the present inventors conducted the following experiment in order to clarify what components contained in barley koji exhibit a fatty liver inhibitory effect through an experiment (Experiment 2) described later. Was. That is, in the above-mentioned publication, hemicellulose obtained from various grains, hemicellulose partially decomposed products, xyloglucan and arabinoxylan have a fatty liver inhibitory effect,
In view of the fact that it is described as having a lipid metabolism improving effect and a liver damage reducing effect, it is speculated that the component having a fatty liver inhibitory effect contained in barley koji is a barley-derived hemicellulose component, The hemicellulose B fraction was fractionated in accordance with a conventional method, and the fatty liver inhibitory effect of the fraction was examined. That is, an alkali is added to barley koji to separate an alkali-soluble fraction, the alkali-soluble fraction is neutralized with an acid to obtain a neutral soluble fraction, and ethanol is added to the neutral soluble fraction. The ethanol-insoluble fraction is collected by this, and the ethanol-insoluble fraction is subjected to lyophilization, and is commonly used when artificially expressing fatty liver in a lyophilized powder of a hemicellulose B fraction obtained by freeze-drying. The experiment was performed by administering a mixture of orotic acid to rats. As a result, the liver weight, liver total lipid concentration, liver cholesterol concentration, and liver triglyceride concentration of the rat showed values equivalent to the normal values, and the serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, and serum phosphorus concentration. The lipid concentration was also equivalent to the normal value, indicating that the development of fatty liver was almost completely suppressed. That is, it was found that the freeze-dried powder of the hemicellulose B fraction obtained from barley koji almost completely suppressed the occurrence of fatty liver. From the above experimental results, it was found that barley koji contains a component that contributes to the suppression of fatty liver, and this component is contained in the hemicellulose B fraction extracted from the barley koji.

As described above, the present inventors added an alkali to barley koji, separated an alkali-soluble fraction, neutralized the alkali-soluble fraction with an acid to obtain a neutral soluble fraction, It has been found that a composition comprising an ethanol-insoluble fraction containing an organic acid, a protein, and hemicellulose, which is fractionated by adding ethanol to the neutral soluble fraction, has a fatty liver inhibitory effect. This discovery of barley koji is a new fact that has never been seen before, and creates a new use of barley koji in which barley koji can be used as food or medicine for therapeutic purposes. Therefore, a main object of the present invention is to provide barley koji with use as food or medicine. Specifically, the present invention provides
An object of the present invention is to provide a composition having an inhibitory effect on fatty liver obtained from barley koji and a method for producing the same.

[0008] As described above, the present inventors have developed Aspergillus.
A filamentous fungus belonging to the genus s is cultured on crushed barley or / and crushed barley barley to obtain a barley koji, an alkali is added to the barley koji, and an alkali-soluble fraction is collected. A neutral soluble fraction is obtained by neutralization with an acid, and a composition comprising an ethanol-insoluble fraction containing an organic acid, a protein, and hemicellulose, which is separated by adding ethanol to the neutral soluble fraction, is a fat. It has been found to have a hepatic inhibitory effect. That is, the present invention provides a method of culturing filamentous fungi belonging to the genus Aspergillus on crushed barley or / and crushed barley barley to obtain barley koji, adding an alkali to the barley koji and separating an alkali-soluble fraction. The alkali-soluble fraction is neutralized with an acid to obtain a neutral soluble fraction, which is fractionated by adding ethanol to the neutral soluble fraction, from an ethanol-insoluble fraction containing organic acids, proteins, and hemicellulose. An object of the present invention is to provide a composition having an inhibitory action on fatty liver and a method for producing the same.

[0009]

As described above, the present invention relates to a composition obtained from barley koji, which contains an organic acid, a protein and hemicellulose and has a fatty liver inhibitory action, and a method for producing the composition. To provide. The present inventors have conducted intensive studies through experiments to achieve the above object, and as a result, culturing filamentous fungi belonging to the genus Aspergillus on crushed barley or / and crushed barley barley to obtain barley koji,
Adding an alkali to the barley koji, separating an alkali-soluble fraction, neutralizing the alkali-soluble fraction with an acid to obtain a neutral soluble fraction, and adding ethanol to the neutral soluble fraction. A composition comprising an ethanol-insoluble fraction collected by the method described above was obtained. The composition contains an organic acid, a protein, and hemicellulose, and has a molecular weight distribution of trace amounts of 100,000 or more, 3% of 30,000 to 100,000, and 40% of 10,000 to 30,000.
%, Molecular weight 3000 to 10,000 16%, molecular weight 1000 to 3000
51% and a molecular weight of 1000 or less are 26%, and the component composition is
Organic acid 41 ± 3% by weight, protein 27 ± 3% by weight, and hemicellulose 26 ± 3% by weight, the sugar composition obtained by hydrolysis with acid, xylose 60 to 70% by weight, arabinose 10 to It turned out to be 20% by weight, 10-15% by weight of glucose, 0-3% by weight of galactose and 0-5% by weight of uronic acid. When the composition was subjected to freeze-drying, it was found that the composition had a white or light brown color and was tasteless and odorless. And it turned out that this composition has an excellent fatty liver inhibitory effect. The present invention is based on these findings. The present invention provides a new use of barley koji that can be used industrially. That is, the present invention provides a food and a medicine comprising a composition having a fatty liver inhibitory action fractionated from barley koji. The present invention also provides
A method for producing the composition is provided.

The composition of the present invention having a fatty liver inhibitory effect obtained from barley koji is obtained by culturing filamentous fungi belonging to the genus Aspergillus on crushed barley or / and crushed barley barley to obtain barley koji. The alkali-soluble fraction is collected by adding an alkali to the mixture, the alkali-soluble fraction is neutralized with an acid to obtain a neutral soluble fraction, and the neutral soluble fraction is fractionated by adding ethanol. A composition comprising an ethanol-insoluble fraction containing an organic acid, protein, and hemicellulose, having a fatty liver inhibitory action. Further, the composition has a molecular weight distribution in which the molecular weight distribution is trace when the molecular weight is 100,000 or more, 3% when the molecular weight is 30,000 to 100,000, 4% when the molecular weight is 10,000 to 30,000, 16% when the molecular weight is 3000 to 10,000, and 1000 to 3000. Is 51% and molecular weight
1000% or less is 26%, and the component composition is 41 ± 3 weight of organic acid
%, Protein 27 ± 3% by weight, and hemicellulose 26 ± 3% by weight, the sugar composition obtained by hydrolysis with an acid was xylose 60 to 70% by weight, arabinose 10 to 20%.
Wt%, glucose 10-15 wt%, galactose 0-3
% By weight, and 0 to 5% by weight of uronic acid. When the composition is freeze-dried, the composition has a white to light brown color and is tasteless and odorless.

The composition of the present invention having a fatty liver inhibitory action fractionated from barley koji is obtained by culturing a filamentous fungus belonging to the genus Aspergillus on crushed barley or / and crushed barley barley to obtain barley koji. The alkali-soluble fraction is collected by adding an alkali to the koji, the alkali-soluble fraction is neutralized with an acid to obtain a neutral soluble fraction, and ethanol is added to the neutral soluble fraction to separate it. It is a composition having an excellent fatty liver inhibitory effect, comprising an ethanol-insoluble fraction containing an organic acid, a protein, and hemicellulose. The composition of the present invention is a barley koji, a fact that has not been clarified at all, that is, barley koji contains a component having a fatty liver inhibitory action, and the component having a fatty liver inhibitory action is the barley. It is based on the fact that the present inventors have revealed that koji can be fractionated as a composition from koji and that the composition can be used as food or medicine. Koji brings new industrially useful uses.

In the present invention, it is preferable to use a white koji mold (Aspergillus kawachii) generally used for producing shochu as a filamentous fungus strain used for obtaining barley koji. In addition, Aspergillus awamor used in the production of awamori
ii) Yellow koji (Aspergillus oryzae) used in sake production
Strain belonging to the genus Aspergillus can also be used. Barley bran-free barley barley used in the present invention refers to a barley bran having a yield of 70% or less that can substantially remove the skin, seed coat, aleurone layer and germ, which are main components of barley bran. This means that any barley that is equal to or less than the percentage of barley may be used. The barley koji used in the present invention is barley bran-free barley barley or / and a liquid culture solution obtained by liquid culture of koji mold using a crushed product of the barley barley, or barley bran-free barley barley or / And a solid culture obtained by solid culture of Aspergillus oryzae using the crushed barley barley. Therefore, as a culture method for obtaining the barley koji,
Either a liquid culture method or a solid culture method may be used.
Moreover, the barley koji used in the production of barley shochu can be used as it is as the barley koji.

In the second step of adding an alkali to the barley koji obtained in the first step to separate an alkali-soluble fraction, a suitable alkali can be added. , Calcium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate and the like can be used. In the third step of obtaining a neutral soluble fraction by removing the precipitate generated by neutralizing the alkali-soluble fraction obtained in the second step with an acid, as the acid, hydrochloric acid, acetic acid, Inorganic or organic acids such as citric acid can be used. In the fourth step of separating the ethanol-insoluble fraction by adding ethanol to the neutral soluble fraction obtained in the third step,
Reagent or industrial ethanol can be used. The ethanol-insoluble fraction obtained in the fourth step contains an organic acid, a protein, and hemicellulose, and has a molecular weight distribution of a trace amount of 100,000 or more, a molecular weight of 30,000 to 100,000, and a molecular weight distribution of 3%. 10,000 to 30,000 is 4
%, Molecular weight 3000 to 10,000 16%, molecular weight 1000 to 3000
It is 51%, the molecular weight is less than 1000, 26%, and the component composition is 41 ± 3% by weight of organic acid, 27 ± 3% by weight of protein, and 26 ± 3% by weight of hemicellulose, obtained by hydrolysis with acid. The sugar composition obtained is 60 to 70% by weight of xylose, 10 to 20% by weight of arabinose, 10 to 15% by weight of glucose, 0 to 3% by weight of galactose, and 0 to 5% by weight of uronic acid, and the ethanol-insoluble fraction. When subjected to freeze-drying,
It is white to light brown and has tasteless and odorless properties.
Hereinafter, experiments performed by the present inventors in completing the present invention will be described in detail. The present invention has been completed based on the knowledge obtained in those experiments.

In view of the above prior art, the present inventors
Since barley koji is derived from barley as a grain, it is predicted that the barley koji may contribute to the treatment of fatty liver,
The study was conducted through experiments. That is, the following experiment 1 was performed in order to clarify whether or not the barley koji crushed product obtained by crushing barley koji has a fatty liver inhibitory effect.

First, barley koji was produced. As a raw material, barley (milled bar 70%) was used. That is, a barley having a barley rate of 70% is made to absorb 40% (W / W) of water, steamed for 40 minutes, then cooled to 40 ° C., and 1 g per 1 kg of barley
Seed koji (white koji mold) is inoculated at 38 ° C and RH95% for 24 hours.
The barley koji was obtained by holding the mixture at 32 ° C. and RH 92% for 20 hours, and the barley koji was pulverized to obtain a barley koji ground product. The barley koji ground product was used in the following experiment 1.

[0016]

[Experiment 1] One 4-week-old male Wistar rat (Japan SLC)
As a group of 6 animals, a basic diet group for ingesting a basic diet generally used as a standard diet when conducting a nutritional experiment, which is commonly used when artificially expressing fatty liver in the basic diet
A control diet group that receives a control diet mixed with 1% orotic acid, and a test diet group in which the control diet is ingested with a test diet mixed with 10% of the barley koji ground material are divided into three groups. The animals were bred with a feed having the composition shown in Table 1 under tap water for 14 days. After the end of the breeding period, weight gain after breeding for 14 days, 14
The daily feed intake was measured, and after dissection of the rat, blood was collected from the heart and the liver was removed. The collected blood was centrifuged to obtain serum, and the obtained serum was subjected to measurement of serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, and serum phospholipid concentration according to a conventional method. Is its weight,
Liver total lipid concentration, liver cholesterol concentration, liver triglyceride concentration, and liver phospholipid concentration were measured.

Serum total cholesterol concentration, serum HDL-
Table 2 shows the measurement results of the cholesterol concentration, serum triglyceride concentration, serum phospholipid concentration, liver weight, liver total lipid concentration, liver cholesterol concentration, and liver triglyceride concentration. The following facts were found from the results shown in Table 2.
That is, the liver weight significantly increased in the control diet group, but the test diet group showed a value slightly shifted toward the normal value direction shown by the basic diet group. On the other hand, the serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, and serum phospholipid concentration decreased in the control diet group, but slightly decreased in the test diet group toward the normal value direction indicated by the basic diet group. The value was closer. In other words, it was found that the test diet in which 10% of barley koji ground material was mixed with a control diet containing 1% orotic acid for artificially expressing fatty liver suppressed the generation of fatty liver, albeit slightly. From these results, it became clear that barley koji had a slight effect of suppressing fatty liver.

Therefore, the following experiment 2 was carried out in order to clarify what components contained in barley koji have the effect of inhibiting fatty liver. That is, the component having a fatty liver inhibitory action contained in barley koji is presumed to be a hemicellulose component derived from barley, and the following hemicellulose B fraction is fractionated from barley koji according to a conventional method, and the fraction is fractionated. The effect of suppressing fatty liver was examined.

[Acquisition of hemicellulose B fraction from barley koji] For the purpose of the following experiment 2, the following hemicellulose B fraction was fractionated from barley koji according to a conventional method. That is, barley koji 10Kg
20 L of water was added thereto, and the mixture was maintained at 55 ° C. for 12 hours to obtain a barley koji saccharified solution.The barley koji saccharified solution was centrifuged at 8,000 rpm for 10 minutes to obtain a solid component. / vol)% calcium hydroxide 10L, hold at 60 ° C for 2 hours with stirring, 1N
After adjusting the pH to 7 using hydrochloric acid, the mixture was centrifuged at 8000 rpm and 10 min to obtain a liquid, and 4 volumes of ethanol was added to the liquid, and the mixture was centrifuged at 8000 rpm and 10 min to remove the ethanol-insoluble fraction. Was collected, and the ethanol-insoluble fraction was subjected to lyophilization to obtain 84 g of a hemicellulose B fraction, and the hemicellulose B fraction was used in Experiment 2 below.

[Experiment 2]

4-week-old male Wistar rats (Japan SLC)
, A group of 6 animals per group, a basic diet group for ingesting a basic diet to be used as a standard diet for nutritional experiments, which is generally used for artificially expressing fatty liver in the basic diet. The control diet group is divided into three groups: a control diet group that receives a control diet mixed with 1% orotic acid, and a test diet group that receives a test diet mixed with 10% of a hemicellulose B fraction obtained from ground barley koji. Each group was allowed to freely feed with a feed having the composition shown in Table 3 together with tap water for 14 days and bred. After the end of the breeding period, the amount of weight gain after breeding for 14 days and the amount of feed intake for 14 days were measured. After dissection of the rats, blood was collected from the heart and the liver was extracted. The collected blood was centrifuged to obtain serum, and the obtained serum was subjected to measurement of serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, and serum phospholipid concentration according to a conventional method. Measured the weight, liver total lipid concentration, liver cholesterol concentration, liver triglyceride concentration, and liver phospholipid concentration.

Serum total cholesterol concentration, serum HDL-
Table 4 shows the measurement results of the cholesterol concentration, serum triglyceride concentration, serum phospholipid concentration, liver weight, liver total lipid concentration, liver cholesterol concentration, and liver triglyceride concentration. The following facts were found from the results shown in Table 4.
Liver weight, liver total lipid concentration, liver cholesterol concentration,
And the liver triglyceride concentration increased remarkably in the control diet group, but the test diet group showed a value substantially equivalent to the normal value. On the other hand, serum total cholesterol concentration, serum HDL
Cholesterol, serum triglyceride, and serum phospholipid levels were reduced in the control diet group,
The test meal group showed a value substantially equivalent to the normal value. That is, hemicellulose B fraction 1 obtained from barley koji ground material was added to a control diet containing 1% orotic acid to artificially express fatty liver.
The test diet mixed with 0% was found to almost completely suppress the development of fatty liver. From these results, it became clear that the hemicellulose B fraction obtained from the ground barley koji had an effect of almost completely suppressing the occurrence of fatty liver. From the above experimental results, the component that contributes to the suppression of fatty liver contained in barley koji is the hemicellulose B
It was revealed that it was contained in the fraction.

Then, the component composition of the hemicellulose B fraction in the liquid residue from the distillation of barley shochu, which was found to have a fatty liver inhibitory effect, was measured by the following method.

[Analysis of Component Composition of Hemicellulose B Fraction Obtained from Barley Koji] As described above, the lyophilized product of the hemicellulose B fraction was added to the liquid component at 2 (wt / v
ol)% After addition of calcium hydroxide, the mixture is adjusted to pH 7 with 1N hydrochloric acid, and thus contains a salt formed during the neutralization. Therefore, an aqueous solution of the freeze-dried product of the hemicellulose B fraction was obtained, and the aqueous solution was subjected to desalting treatment. Thereafter, a conventional HPLC method was used for organic acids, a Kjeldahl method for proteins, and PJ Van for hemicellulose.
The method of Soest et al. [Proc. Nutr. Soc., 32, 123 (1973)], and the water content were measured by a normal pressure heating drying method.
Table 5 shows the analysis results of the component composition of the hemicellulose B fraction. As is clear from the results shown in Table 5, the hemicellulose B fraction contained 41 ± 3% by weight of organic acid,
It was found that the composition contained ± 3% by weight and 26 ± 3% by weight of hemicellulose. From the above, it was found that the composition comprising the hemicellulose B fraction of the present invention contained an organic acid in an amount equal to or greater than hemicellulose. In addition, a composition mainly comprising a water-soluble polysaccharide having a conventionally known liver function improving action, that is, an alcoholic liver injury reducing substance described in JP-A-4-360835, JP-A-3-285653. Improved lipid metabolism described, hemicellulose described in JP-A-1-242530, hemicellulose partially decomposed product described in JP-A-5-43470, JP-A-7-147934 and JP-A-9-224608. The described xyloglucan and its enzymatically decomposed product do not contain any organic acid in view of the contents of these publications. In this respect, it is clear that the composition comprising the hemicellulose B fraction of the present invention is clearly different from the conventionally known composition containing a water-soluble polysaccharide having a liver function improving action as a main component. . By the way, as described above, when measuring the component composition, the hemicellulose B fraction after subjecting to desalting treatment was used as a sample, but the same test as in Experiment 4 was performed using the same sample. In the same manner as in Experiment 4 using the hemicellulose B fraction before subjecting to desalting treatment, an excellent inhibitory effect on fatty liver was observed.

The sugar composition of hemicellulose contained in the hemicellulose B fraction obtained from barley koji, which was found to have a fatty liver inhibitory effect, was measured by the following method.

[0023]

[Analysis of sugar composition of hemicellulose B fraction obtained from barley koji] 1 ml of ion-exchanged water was added to 0.05 g of the lyophilized product of the hemicellulose B fraction, and 200 μl of concentrated hydrochloric acid was added thereto. Hydrolysis was performed for 4 hours, and the mixture was filtered through a 0.80 μm membrane filter to obtain a filtrate.The filtrate was injected into a high-performance liquid chromatograph to obtain the hemicellulose B.
The sugar composition of the fraction was determined. High-performance liquid chromatographic analysis was performed using Waters 600 manufactured by Waters, and a differential refractometer RI-71 manufactured by Showa Denko KK was used as a detector.
A minex HPX-87H (300 mm x 7.8 mm) was used. The column temperature was 60 ° C, the mobile phase was 5 mM sulfuric acid, and the flow rate was 0.5 ml / m
In, the sample injection volume was 20 μl.

Table 6 shows the analysis results of the sugar composition of hemicellulose contained in the hemicellulose B fraction. As is clear from the results shown in Table 6, the sugar composition of hemicellulose contained in the hemicellulose B fraction obtained from the barley koji of the present invention is 60 to 70% by weight of xylose and 10 to 20% of arabinose.
% Of glucose, 10 to 15% by weight of glucose, 0 to 3% by weight of galactose and 0 to 5% by weight of uronic acid. The ratio of arabinose content to xylose content was 0.15 to 0.3. On the other hand, the following is known regarding the sugar composition of a composition containing a conventionally known water-soluble polysaccharide having a liver function improving action as a main component. That is,
JP-A-4-360835 discloses that the sugar composition of an alcoholic liver injury-reducing substance containing arabinoxylan as an active ingredient is 25 to 45% by weight of xylose, 20 to 35% by weight of arabinose, 1 to 10% by weight of glucose, and uronic acid. It is described as being 1 to 7% by weight, galactose 0.5 to 3% by weight, and mannose (trace amount). Further, JP-A-3-285653 discloses that the sugar composition of a lipid metabolism-improved product containing cereal gum as an active ingredient is xylose 2 to 15% by weight, arabinose 2 to 15% by weight, glucose 70% by weight or more, uronic acid. It is described as a trace, a galactose trace, and a mannose trace.

The following is also known regarding the saccharide composition of a composition containing a conventionally known water-soluble polysaccharide as a main component, the presence or absence of a liver function improving effect is unknown. That is, JP-A-5-112455 discloses that the sugar composition of a colorectal cancer inhibitor containing arabinoxylan as a main component is xylose 25 to
It describes that 45% by weight, 20-35% by weight of arabinose, 1-10% by weight or more of glucose, 1-7% by weight or more of uronic acid, 0.5-3% by weight or more of galactose, and trace amount of mannose. JP-A-10-237107 discloses that the sugar composition of a water-soluble polysaccharide having excellent emulsifying power containing arabinoxylan derived from a cell wall of a grass plant as a main component has a weight ratio of xylose / arabinose of 2.1 / 1 to 1.9 / 1. Is described.
Japanese Patent Application Laid-Open No. 9-23895 discloses that the sugar composition of the immunity enhancer containing a water-soluble polysaccharide as a main component is xylose 54% by weight, arabinose 22% by weight, glucose 6% by weight, uronic acid 1 to
7% by weight, galactose 5% by weight, mannose 8% by weight, other sugars 5% by weight, or xylose 48% by weight, arabinose 2
It is described to be 6% by weight, 6% by weight of glucose, 7% by weight of galactose, 9% by weight of mannose, and 4% by weight of other sugars.

As is apparent from the above description, the hemicellulose having the above sugar composition contained in the composition having the inhibitory effect on fatty liver obtained from the barley koji of the present invention can be obtained by using the respective water-soluble products obtained from various conventional cereals. The content ratio of xylose was extremely higher than the sugar composition of the water-soluble polysaccharide, and it was found that the water-soluble polysaccharide obtained from each of the grains had a sugar composition distinctly different from that of the water-soluble polysaccharide. By the way, JP-A-6-217761 discloses that the sugar composition of a useful intestinal bacterial growth promoter containing water-soluble arabinoxylan as an active ingredient has a ratio of xylose: arabinose of 1: 0.32, and this value is described. It is similar to the ratio of xylose: arabinose of hemicellulose contained in the composition having a fatty liver inhibitory effect obtained from the above-described barley koji of the present invention, from 1: 0.15 to 1: 0.3. Then, the molecular weight distribution of the hemicellulose B fraction was measured, and the molecular weight distribution was compared with the molecular weight distribution of the intestinal useful bacteria growth promoter.

[0027]

[Measurement of molecular weight distribution of hemicellulose B fraction obtained from barley koji] Showdex Denko Co., Ltd. Shodex standard P-82 (molecular weight 1300-1660000) and a molecular weight standard product consisting of maltotriose (molecular weight 504) were separately prepared. 0.1mol
/ L sodium nitrate solution to obtain a standard solution having a concentration of 0.05 W / V%. The standard solution was injected into a high performance liquid chromatograph to prepare a calibration curve. Next, 0.02 g of a freeze-dried product of the hemicellulose B fraction was prepared, and 10 ml of a 0.1 mol / L sodium nitrate solution was added thereto.
A filtrate was obtained by filtration through a μm membrane filter, and the filtrate was injected into a high-performance liquid chromatograph, and the molecular weight distribution was determined using a 480 data station GPC program manufactured by System Instruments. High-performance liquid chromatograph analysis is performed by Shodex GPC SYSTEM-
Using a differential refractometer RI-7 manufactured by Showa Denko KK
Use 1S, column is TSKgel GMPWXL manufactured by Tosoh Corporation
(φ7.8 mm × 300 mm) were used in combination. The column temperature was 40 ° C., the mobile phase used was a 0.1 mol / L sodium nitrate solution, the flow rate was 1.0 ml / min, and the sample injection volume was 100 μl.

Table 7 shows the measurement results of the molecular weight distribution of the hemicellulose B fraction. As is clear from the results shown in Table 7, the hemicellulose B fraction has a trace molecular weight of 100,000 or more, a molecular weight of 30,000 to 100,000 3%, a molecular weight of 10,000 to 30,000 4%,
A molecular weight of 3000 to 10,000 is 16%, a molecular weight of 1000 to 3000 is 51%,
It has a molecular weight distribution with a molecular weight of 1000 or less being 26%. On the other hand, the following is described regarding the molecular weight of a conventionally known composition mainly composed of a water-soluble polysaccharide having a liver function improving action. That is, JP-A-4-360835 describes that an alcoholic liver injury-reducing substance containing arabinoxylan as an active ingredient has a weight average molecular weight of about 100,000 or more, and JP-A-3-285653 discloses that It is described that the lipid metabolism-improved product containing cereal gum as an active ingredient has a weight average molecular weight of 100,000 to 1,000,000. JP-A-5-112455 discloses that a colorectal cancer inhibitor containing arabinoxylan as a main component has a weight-average molecular weight of about 100,000 or more. It is described that a water-soluble polysaccharide having excellent emulsifying power containing arabinoxylan derived from a plant cell wall as a main component has a weight average molecular weight of 10,000 to 1,000,000. Further, Japanese Patent Application Laid-Open No. 9-23895 describes that the immunity enhancing substance mainly composed of a water-soluble polysaccharide has an average molecular weight of 600,000 or 650,000.

As is apparent from the above description, the hemicellulose B fraction containing organic acid, protein and hemicellulose obtained from the barley koji of the present invention has a molecular weight of 100%.
0 to 3000 as main components (see Table 7),
The hemicellulose B fraction is described in the above-mentioned JP-A-4-360835, JP-A-3-285653, JP-A-5-112455 and JP-A-10-237107, to the respective water-soluble polysaccharides described therein. It has a clearly lower molecular weight. And the hemicellulose B fraction contains the same amount or more of organic acids and proteins as the hemicellulose. From this, it is clear that the hemicellulose B fraction is clearly different from the respective water-soluble polysaccharides described in the above publications. In addition, from the viewpoint of mere `` molecular weight distribution '', the useful intestinal bacterial growth promoter containing water-soluble arabinoxylan described in JP-A-6-217761 as an active ingredient has a molecular weight of 1500 to 7000, and the molecular weight range is 1500.
-7000 seem to overlap with the molecular weight range of 1000-3000 which is the main component of the composition of the present invention. However, the useful intestinal bacterial growth promoter described in JP-A-6-217761 is a water-soluble polysaccharide mainly containing a water-soluble arabinoxylan containing no organic acid as in the composition of the present invention. . On the other hand, the hemicellulose B fraction is a composition containing the same amount or more of organic acid and protein as hemicellulose. In this regard, it is not possible to simply compare the molecular weight of the useful enteric bacteria growth promoter of 1500 to 7000 with the molecular weight range of the hemicellulose B fraction of 1000 to 3000. And, as will be apparent from Test Example 2 described below, the fatty liver inhibitory effect of the composition comprising the hemicellulose B fraction of the present invention is a useful intestinal bacterial growth promoter described in JP-A-6-217761. Is extremely high as compared with the fatty liver inhibitory effect of the compound. From this, the hemicellulose B fraction is clearly different from the useful intestinal bacterial growth promoter. From the above, in the present invention obtained from barley koji, organic acids, proteins,
And a composition having a fatty liver inhibitory action containing hemicellulose is apparent from the viewpoint of the component composition, sugar composition, molecular weight distribution and fatty liver inhibitory effect with the cereal-derived water-soluble polysaccharide described in the above-mentioned publication. Was found to be different.

[0030]

BEST MODE FOR CARRYING OUT THE INVENTION

[0031]

EXAMPLES The present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.

[0032]

Example 1 First, barley koji was produced. As a raw material, barley (milled bar 70%) was used. That is, a barley having a barley rate of 70% is made to absorb 40% (W / W) of water, steamed for 40 minutes, then cooled to 40 ° C., and 1 g per 1 kg of barley
Inoculated with Aspergillus oryzae (Aspergilluskawachii), 38
24 ° C., RH 95%, 20 hours at 32 ° C., RH 92%
Barley koji was produced by holding for a time.

To 10 kg of the barley koji, add 20 L of water,
Hold for 2 hours to obtain a barley koji saccharified solution, the barley koji saccharified solution 800
A solid content was obtained by centrifugation at 0 rpm and 10 min, and 10 L of 2 (wt / vol)% calcium hydroxide was added to the solid content, and the mixture was kept at 60 ° C. for 2 hours with stirring, and using 1N hydrochloric acid. After adjusting to pH 7,
A liquid fraction was obtained by centrifugation at 8000 rpm for 10 min, a four-fold volume of ethanol was added to the liquid fraction, and the mixture was centrifuged at 8000 rpm for 10 min to separate an ethanol-insoluble fraction. The mixture was freeze-dried using a vacuum freeze-dryer, and the resulting freeze-dried product (84 g) was crushed to give a white or pale brown, tasteless and odorless composition. The composition has a molecular weight distribution of a trace amount of 100,000 or more, a molecular weight of 30,000 to 100,000, 3%, and a molecular weight of 10,000 to 30,000,
%, Molecular weight 3000 to 10,000 16%, molecular weight 1000 to 3000
51% and a molecular weight of 1000 or less are 26%, and the component composition is
Organic acid 41 ± 3% by weight, protein 27 ± 3% by weight, and hemicellulose 26 ± 3% by weight, the sugar composition obtained by hydrolysis with acid, xylose 60 to 70% by weight, arabinose 10 to It turned out to be 20% by weight, 10-15% by weight of glucose, 0-3% by weight of galactose and 0-5% by weight of uronic acid.

The composition obtained in Example 1 was subjected to the following Test Example 1 to evaluate the inhibitory action of the composition on fatty liver.

[Test Example 1] The following Test Example 1 was carried out in order to clarify the inhibitory effect on fatty liver caused by orotic acid administration of the composition obtained in Example 1. That is, a 4-week-old Wistar male rat (Japan SLC) is a group of 6 rats per group, and a basic diet group for ingesting a basic diet which is generally used as a standard diet when performing nutritional experiments. A control diet group that receives a control diet mixed with 1% orotic acid, which is commonly used when artificially expressing the liver, and a test diet in which the control diet is fed with a test diet mixed with 2% of the composition of the present invention. Each group was bred with a feed having the composition shown in Table 8 freely fed with tap water for 14 days. After the end of the breeding period, the amount of weight gain after breeding for 14 days and the amount of food intake for 14 days were measured. After dissection of the rats, blood was collected from the heart and the liver was extracted.
The collected blood was centrifuged to obtain serum, and the obtained serum was subjected to measurement of serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, and serum phospholipid concentration according to a conventional method. Measured the weight, liver total lipid concentration, liver cholesterol concentration, liver triglyceride concentration, and liver phospholipid concentration.

[0035]

[Evaluation 1] Results of measurement of serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, serum phospholipid concentration, liver weight, liver total lipid concentration, liver cholesterol concentration, and liver triglyceride concentration are shown.
See Figure 9. The following facts were found from the results shown in Table 9. Liver weight increased in the control diet group, and in the test diet group, it was substantially equivalent to the normal value of the basal diet. Liver total lipid concentration, liver cholesterol concentration, and liver triglyceride concentration
The control diet group increased remarkably, but the test diet group showed a value substantially equal to or lower than the normal value of the basal diet. On the other hand, serum total cholesterol concentration, serum HD
The L-cholesterol concentration, serum triglyceride concentration, and serum phospholipid concentration decreased in the control diet group, while the test diet group showed values substantially equivalent to the normal values of the basal diet. That is, in the test diet group in which the composition of the present invention obtained from barley koji was mixed with the control diet containing orotic acid that artificially expresses fatty liver, fatty liver was almost completely suppressed. From these results, it is difficult to find a difference from the base diet group containing no orotic acid in the test diet group in which the composition of the present invention is mixed with the control diet containing orotic acid that artificially expresses fatty liver. It became clear that fatty liver was almost completely suppressed.

As is clear from the results of Test Example 1, the composition obtained from barley koji of the present invention and containing an organic acid, protein, and hemicellulose and having an inhibitory effect on fatty liver was obtained by administering orotic acid to a fatty acid. The liver was found to be almost completely suppressed.

In order to compare the inhibitory effect of the composition of the present invention on fatty liver by administration of orotic acid, and the inhibitory effect of a water-soluble polysaccharide having a conventionally known action of improving fatty liver on fatty liver by administration of orotic acid, the following was performed. Test Example 2 was performed. First, conventionally known various water-soluble polysaccharides having a fatty liver improving effect were prepared according to the following method.

[0038]

[Preparation of water-soluble polysaccharide] Fatty liver inhibitor (JP-A-1
Preparation of Japanese Patent Application Laid-Open No. 1-242530 A fatty liver inhibitor comprising wheat bran hemicellulose described in JP-A-1-242530 was prepared by the following method. That is, commercially available wheat bran was stirred and washed with distilled water, and then sieved with 30 mesh to obtain a prepared wheat bran.To 3 kg of the prepared wheat bran, 30 L of water added with 2% calcium hydroxide was added, and 80 wt. C. for 5 hours to obtain an extract, and the extract was subjected to 5000 r
pm, centrifuged under the conditions of 10 minutes to obtain a liquid component.The liquid component was adjusted to pH 7 with sulfuric acid, followed by filtration and decoloration to obtain a molecular weight cutoff of 10
The fraction having a molecular weight of 100,000 or less was removed using a 10,000 ultrafiltration membrane, desalted and concentrated, followed by freeze-drying to obtain 171 g of a fatty liver inhibitory substance consisting of wheat bran hemicellulose. 2. Preparation of Alcoholic Liver Damage Reducing Substance (Japanese Unexamined Patent Publication No. 4-360835) An alcoholic liver damage reducing substance containing rice bran-derived arabinoxylan as an active ingredient described in Japanese Unexamined Patent Publication No. 4-360835 was prepared by the following method. That is, to 10 kg of defatted rice bran, 50 L of hot water at about 90 ° C. and 100 g of thermostable amylase were added, and the mixture was stirred with a mixer, gelatinized and the starch released in the aqueous solution was 5,000 rpm, 1 rpm.
A residue was obtained by centrifugation under the condition of 0 minutes, 25 L of a 2% calcium hydroxide solution was added to 5 kg of the residue, and the mixture was stirred and extracted at 60 ° C for 2 hours to obtain an extract, and hydrochloric acid was added to the extract to adjust the pH to 7. 5000r after adjustment
pm, 10 minutes, and then centrifuged at 7200 rpm for 10 minutes to obtain a separated solution, and the separated solution was subjected to ultrafiltration with a molecular weight cutoff of 100,000 to remove a fraction having a molecular weight of 100,000 or less. After desalting and concentration, the mixture was freeze-dried to obtain 327 g of an alcoholic liver injury reducing substance containing arabinoxylan as an active ingredient. 3. Preparation of Alcoholic Fatty Liver Inhibitor (JP-A-5-43470) As an alcoholic fatty liver-inhibiting substance containing as a main component a partially decomposed product of hemicellulose obtained from corn fiss as described in JP-A-5-43470. "Cell Ace" (trade name, manufactured by Nippon Shokuhin Kako Co., Ltd.) was used as it was. 4. Preparation of lipid metabolism-improved product (JP-A-3-285653) A lipid-metabolism-improved product described in JP-A-3-285653 and containing barley-derived β-glucan as a main component was prepared by the following method.
That is, 30 L of distilled water was added to 6 kg of refined barley flour (73% refined yield), and a 20% sodium carbonate solution was added to adjust the pH to 10.
An extract was obtained by stirring and extracting at 5 ° C. for 30 minutes, and the extract was
The liquid component 1 and the residue were collected by centrifugation at 0 rpm and 10 minutes, and the residue was further extracted twice using the above method to obtain a liquid component 2, and the liquid component 2 was added to the liquid component 1. In addition, an extract was obtained, and 2M hydrochloric acid was added to the extract to adjust the pH to 4.5.
A supernatant was obtained by centrifugation at 0 minutes, and the supernatant was concentrated under reduced pressure to 1/5 volume using a rotary evaporator, and a 4-fold volume of ethanol was added to obtain a solid content. Was washed with 10 L of ethanol, air-dried, and then pulverized to obtain 165 g of a lipid metabolism-improved product mainly composed of barley-derived β-glucan. 5. Useful intestinal bacterial growth promoter (JP-A-6-217761)
Preparation of Intestinal Useful Bacteria Growth Promoter Using Wheat Bran-Derived Water-Soluble Arabinoxylan described in JP-A-6-217761 as an active ingredient was prepared by the following method. That is, 4 kg of wheat bran was washed with water to obtain a washed wheat bran, 10 L of water was added to 5 kg of the washed wheat bran, mixed, and then heat-treated at 120 ° C. and 2.1 atm for 10 minutes. Degrading enzyme (trade name “Cellulase Onozuka RS”, manufactured by Yakult Honsha Co., Ltd.)
Add 10 g, and after holding for 10 minutes, immediately boil to inactivate the enzyme, centrifuge at 10,000 G for 10 minutes to obtain a liquid, and subject the liquid separated to lyophilization to obtain wheat bran. 622 g of a useful intestinal bacteria growth promoter containing water-soluble arabinoxylan as an active ingredient was obtained.

[0039]

[Test Example 2] A 4-week-old Wistar male rat (Japan SLC) was used.
As a group of 6 animals, a basic diet group for ingesting a basic diet generally used as a standard diet when conducting a nutritional experiment, which is commonly used when artificially expressing fatty liver in the basic diet
A control diet group in which a control diet mixed with 1% orotic acid is given, a test diet group in which the control diet is ingested with a test diet mixed with 2% of the composition of the present invention, and the control diet is described in JP-A-1-242530. A comparative diet A group in which a comparative diet A mixed with 2% of the above-mentioned fatty liver inhibitor is mixed, and the control diet is mixed with 2% of the alcoholic liver injury reducing substance described in JP-A-4-360835. Comparative food B group ingesting food B, JP-A-5-43470 to the control food
Comparative food group C in which a comparative food C mixed with 2% of an alcoholic fatty liver inhibitor described in Japanese Patent Publication No.
Japanese Patent Application Laid-Open No. 3-285653 discloses a comparative diet D group for ingesting a comparative diet D mixed with 2% of the lipid metabolism-improved product,
6-217761 JP-A-2%
The group was divided into eight groups, a comparative diet E group in which a comparative diet mixed with was fed, and each group was fed a feed having a composition shown in Table 10 freely with tap water for 14 days. After the end of the breeding period, 14
The amount of body weight gain after 14 days of breeding and the amount of food intake for 14 days were measured, and after dissection of the rat, blood was collected from the heart and the liver was extracted. The collected blood was centrifuged to obtain serum, and the obtained serum was subjected to measurement of serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, and serum phospholipid concentration according to a conventional method. Measured the weight, liver total lipid concentration, liver cholesterol concentration, liver triglyceride concentration, and liver phospholipid concentration.

[0040]

[Evaluation 2] The measurement results of serum total cholesterol concentration, serum HDL-cholesterol concentration, serum triglyceride concentration, serum phospholipid concentration, liver weight, liver total lipid concentration, liver cholesterol concentration, and liver triglyceride concentration are shown.
See Figure 11. The following facts were found from the results shown in Table 11.
Liver weight showed substantially the same value as the normal value of the basal diet in the test diet group, while all of the comparative diet A to comparative diet E groups were substantially equivalent to the normal value of the basic diet. No value was shown. The liver total lipid concentration, liver cholesterol concentration, and liver triglyceride concentration were substantially equal to or lower than the normal value of the basic diet in the test diet group, but were lower than the normal diet. None of the comparative diet E groups showed values substantially equivalent to the normal values of the basal diet. On the other hand, serum total cholesterol concentration, serum HDL-cholesterol concentration,
The serum triglyceride concentration and the serum phospholipid concentration were substantially the same as the normal value of the basic diet in the test diet group, while the comparative diet group A to the comparative diet E group were all in the basic diet. It did not show a value substantially equivalent to the normal value. That is, the test diet group obtained by mixing the composition of the present invention obtained from barley koji with a control diet containing orotic acid that artificially expresses fatty liver almost completely suppressed fatty liver, whereas the known diet None of the water-soluble polysaccharides having a liver-improving action completely suppressed fatty liver. From the above results, the composition of the present invention may be a composition having a fatty liver inhibitory effect having a fatty liver inhibitory effect that is clearly superior to various water-soluble polysaccharides having a conventionally known fatty liver improving effect. found.

[0041]

As described in detail above, Aspergil of the present invention
A filamentous fungus belonging to the genus lus is cultured on crushed barley or / and crushed barley barley to obtain a barley koji, an alkali is added to the barley koji, and an alkali-soluble fraction is collected. A neutral soluble fraction is obtained by neutralization with an acid, and a composition comprising an ethanol-insoluble fraction containing an organic acid, a protein, and hemicellulose, which is separated by adding ethanol to the neutral soluble fraction, is used. If so, a remarkable effect of suppressing fatty liver can be obtained.

[0042]

[Table 1]

[0043]

[Table 2]

[0044]

[Table 3]

[0045]

[Table 4]

[0046]

[Table 5]

[0047]

[Table 6]

[0048]

[Table 7]

[0049]

[Table 8]

[0050]

[Table 9]

[0051]

[Table 10]

[0052]

[Table 11]

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁷ Identification symbol FI Theme coat ゛ (Reference) A61P 3/06 A61P 3/06 C12N 1/14 C12N 1/14 B // (C12N 1/14 (C12N 1 / 14 B C12R 1:66) C12R 1:66) (72) Inventor Satoshi Mochizuki 6-31-603 Tamurocho, Oita City, Oita Prefecture Serpas Tamuro (72) Inventor, Akiko Miyamoto 62-ga, Matsugaoka, Oita City, Oita Prefecture 18 (72) Inventor Miwako Hagiwara 1-118 Oji, Mie-cho, Ono-gun, Oita

Claims (12)

[Claims] 1. A filamentous fungus belonging to the genus Aspergillus is cultivated on barley bran-free pearl barley or / and crushed barley barley to obtain barley koji, and alkali is added to the barley koji to obtain an alkali-soluble fraction. , The alkali-soluble fraction is neutralized with an acid to obtain a neutral soluble fraction, and the organic acid, protein, and hemicellulose separated by adding ethanol to the neutral soluble fraction. A composition having an action of inhibiting fatty liver, comprising an ethanol-insoluble fraction having the following molecular weight distribution and component composition. (A) Molecular weight distribution: molecular weight of 100,000 or more, trace amount 30,000 to 103,000% 10,000 to 30,000% 3000 to 10,000%, 1000 to 3000 51%, 1000 or less 26% (b) component composition: organic acid 41 ± 3% by weight, protein 27 ± 3
Wt%, and hemicellulose 26 ± 3 wt%. 2. The composition according to claim 1, wherein the organic acid comprises citric acid, malic acid, succinic acid, and lactic acid, and the protein includes a peptide and an amino acid. . 3. The hemicellulose is xylose 60 to 7
0% by weight, arabinose 10-20% by weight, glucose 10-15% by weight, galactose 0-3% by weight, and uronic acid 0
2. The composition having a fatty liver inhibitory activity according to claim 1, having a sugar composition of from 5 to 5% by weight. 4. The composition according to claim 1, wherein the composition comprises a dry powder of the ethanol-insoluble fraction. 5. The barley percentage of the barley barley is at least 7
The composition having an inhibitory action on fatty liver according to claim 1, which is 0%. A food comprising the composition according to claim 1. A pharmaceutical comprising the composition according to claim 1. 8. A step of culturing a filamentous fungus belonging to the genus Aspergillus on barley bran-free barley-free barley or / and a crushed barley barley to obtain a barley koji, adding an alkali to the barley koji to obtain an alkali-soluble fraction. Separating the neutral soluble fraction with an acid to obtain a neutral soluble fraction, and adding ethanol to the neutral soluble fraction to obtain an organic acid, protein, and hemicellulose. And producing an ethanol-insoluble fraction having the following molecular weight distribution and component composition. (A) Molecular weight distribution: molecular weight of 100,000 or more, trace amount 30,000 to 103,000% 10,000 to 30,000% 3000 to 10,000%, 1000 to 3000 51%, 1000 or less 26% (b) component composition: organic acid 41 ± 3% by weight, protein 27 ± 3
Wt%, and hemicellulose 26 ± 3 wt%. 9. The composition according to claim 8, wherein the organic acid comprises citric acid, malic acid, succinic acid, and lactic acid, and the protein includes a peptide and an amino acid. Manufacturing method. The hemicellulose may be xylose 60 or more.
70% by weight, arabinose 10-20% by weight, glucose 10-15% by weight, galactose 0-3% by weight, and uronic acid 0
9. The method for producing a composition having a fatty liver inhibitory action according to claim 8, wherein the composition has a sugar composition of from 5 to 5% by weight. 11. The method for producing a composition having a fatty liver inhibitory action according to claim 8, further comprising a step of freeze-drying the ethanol-insoluble fraction. 12. The barley having a barley yield of at least 70.
9. The method for producing a composition having a fatty liver inhibitory effect according to claim 8, wherein the composition is%.